GLP-1 medications were created to treat metabolic conditions like obesity and type 2 diabetes
O revizuire a 41 de studii care au implicat 2 900 de persoane a fost publicat n 2023, sugernd c suplimentarea cu L-carnitin poate: reduce glicemia i nivelul hemoglobinei la jeun, reduce indicele de rezisten la insulin HOMA-IR, s mbunteasc sensibilitatea la insulin la persoanele cu diabet, supraponderalitate sau obezitate, s contribuie la mbuntirea funciei celulelor pancreatice responsabile de producerea insulinei
Individuals who experience nausea from GLP-1 medications tend to be more common when first starting treatment or increasing the dosage
R., Yeap, S
These symptoms also overlap with other conditions, so its worth testing before starting treatment
R., Elmahdy, H., El-Dib, M., Elbatch, M